Black Diamond Therapeutics (BDTX) Other Non-Current Liabilities (2018 - 2019)
Black Diamond Therapeutics (BDTX) posted Other Non-Current Liabilities of $16000.0 for Q4 2019, down 99.6% on a QoQ basis from $4.0 million in Q4 2018, and down 99.6% year-over-year from $4.0 million in Q4 2018.
Black Diamond Therapeutics (BDTX) Other Non-Current Liabilities (2018 - 2019) Analysis & Trends
Black Diamond Therapeutics' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $16000.0 for Q4 2019.
- Quarterly Other Non-Current Liabilities fell 99.6% year-over-year to $16000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $16000.0 (down 99.6% YoY) and the FY2019 annual result came in at $16000.0, down 99.6% from the prior year.
- Other Non-Current Liabilities was $16000.0 for Q4 2019 at Black Diamond Therapeutics, down from $4.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $4.0 million in Q4 2018 and bottomed at $16000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Black Diamond Therapeutics | 99.59 Mn | -18.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 16,000.00 |
| Dec 31, 2018 | 4.02 Mn |